Article

Persistent Severe PH Predicts Death One Year Post-TAVR

Improvements in PH at one-month post-TAVR are not sustained and are not linked to lower mortality.

 

What is the incidence of severe pulmonary hypertension after transcatheter aortic valve replacement and does it have prognostic value?

 

 

 

PH improvement one month after TAVR plateaus and this early improvement is not associated with lower mortality.

 

 

The association of persistent severe PH after TAVR with mortality is far stronger than that of baseline severe PH with mortality. This may reflect cases wherein the improved hemodynamic post-TAVR cannot improve pulmonary circulation.

 

 

 

Excluded were patients with past failed aortic bioprosthesis and past mitral valve surgery. Patients were divided into 3 groups based on severity of PH in order to observe impact on QOL, prognosis, and outcomes. 

 

 

One-month outcomes: No difference in overall or cardiac mortality across groups.

 

 

 


One-year outcomes: Overall mortality: 1.5 times higher risk in group 2, 2.3 times higher risk in group 3, vs group 1. Cardiac mortality: 1.3 times higher risk in group 2, 1.7 times higher risk in group 3, vs group 1.

 


Independent predictors of 1-year mortality: baseline sPAP >60 mm Hg; persitent severe PH after 1 month; CrC <30 mL/min; severe mitral regurgitation.

 

 

The authors conclude that even in cases where PH is irreversible the positive ipmact on QOL means that even is severe PH persists, global status may be improved.

 

 

 

Authors also note that further studies are needed to evaluate whether changes in pulmonary circulation become irreversible at an advanced stage of PH, even with aortic valve replacement and reduction of left-sided filling pressure.

Source: Testa L, Latib A, De Marco F, et al. Persistence of severe pulmonary hypertension after transcatheter aoritic valve replacement: incidence and prognostic impact. Circ Cardiovasc Interv. 2016;9(6).

Related Videos
Experts' Perspectives: Top Stories in Cardiology for 2024
Yehuda Handelsman, MD: Insulin Resistance in Cardiometabolic Disease and DCRM 2.0 | Image Credit: TMIOA
Nathan D. Wong, MD, PhD: Growing Role of Lp(a) in Cardiovascular Risk Assessment | Image Credit: UC Irvine
Laurence Sperling, MD: Expanding Cardiologists' Role in Obesity Management  | Image Credit: Emory University
Laurence Sperling, MD: Multidisciplinary Strategies to Combat Obesity Epidemic | Image Credit: Emory University
Matthew J. Budoff, MD: Examining the Interplay of Coronary Calcium and Osteoporosis | Image Credit: Lundquist Institute
Orly Vardeny, PharmD: Finerenone for Heart Failure with EF >40% in FINEARTS-HF | Image Credit: JACC Journals
Matthew J. Budoff, MD: Impact of Obesity on Cardiometabolic Health in T1D | Image Credit: The Lundquist Institute
Matthew Weir, MD: Prioritizing Cardiovascular Risk in Chronic Kidney Disease | Image Credit: University of Maryland
© 2025 MJH Life Sciences

All rights reserved.